Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
6.16
USD
|
-9.54%
|
|
+0.16%
|
+43.93%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
119.7
|
89.28
|
65.58
|
46.52
|
66.27
|
-
|
-
|
Enterprise Value (EV)
1 |
119.7
|
89.28
|
65.58
|
46.52
|
66.27
|
66.27
|
66.27
|
P/E ratio
|
-14.1
x
|
-7.06
x
|
-4.61
x
|
-2.91
x
|
-2.61
x
|
-3.24
x
|
-4.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-7,094,197
x
|
-4,954,807
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-8,416,928
x
|
-5,125,032
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,218
|
11,188
|
10,857
|
10,869
|
10,759
|
-
|
-
|
Reference price
2 |
19.25
|
7.980
|
6.040
|
4.280
|
6.160
|
6.160
|
6.160
|
Announcement Date
|
3/10/21
|
3/10/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-12.58
|
-13.23
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.908
|
-12.59
|
-14.43
|
-17.88
|
-26.6
|
-30.74
|
-38.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-5.908
|
-12.36
|
-14.26
|
-15.96
|
-24.1
|
-25.21
|
-
|
Net income
1 |
-5.908
|
-12.36
|
-14.26
|
-15.96
|
-23.3
|
-27.66
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.370
|
-1.130
|
-1.310
|
-1.470
|
-2.360
|
-1.900
|
-1.490
|
Free Cash Flow
|
-
|
-10.61
|
-12.8
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/21
|
3/10/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-4.147
|
-3.509
|
-4.064
|
-
|
-1.841
|
-3.493
|
-3.949
|
-4.794
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.149
|
-3.511
|
-4.066
|
-4.395
|
-2.145
|
-3.826
|
-4.286
|
-5.19
|
-3.524
|
-4.877
|
-5.732
|
-6.3
|
-6.9
|
-7.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.054
|
-3.54
|
-4.122
|
-4.492
|
-2.265
|
-3.381
|
-3.868
|
-4.746
|
-3.161
|
-4.186
|
-5.441
|
-
|
-
|
-
|
Net income
1 |
-4.054
|
-3.54
|
-4.122
|
-4.492
|
-2.265
|
-3.381
|
-3.868
|
-4.746
|
-3.161
|
-4.186
|
-5.441
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3600
|
-0.3100
|
-0.3800
|
-0.4100
|
-0.2100
|
-0.3100
|
-0.3600
|
-0.4400
|
-0.2900
|
-0.3800
|
-0.5100
|
-0.5600
|
-0.6200
|
-0.6800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/1/21
|
3/10/22
|
5/3/22
|
8/8/22
|
11/7/22
|
3/20/23
|
5/9/23
|
8/9/23
|
11/8/23
|
3/18/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-10.6
|
-12.8
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.03
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/21
|
3/10/22
|
3/20/23
|
3/18/24
|
-
|
-
|
Last Close Price
6.16
USD Average target price
22
USD Spread / Average Target +257.14% Consensus |
1st Jan change
|
Capi.
|
---|
| +43.93% | 66.27M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|